MapLight Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for MapLight Therapeutics (MPLT).

Price Target Range — 4 Quarters

Analyst Consensus — 12 Analysts

1S.Buy

9Buy

2Hold

Consensus RatingBuy# Analysts12Avg. Consensus PT$32Upside to Avg. PT+328.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 6, 2026	Guggenheim	Delma Caiati	Initiate	Neutral	—
Aug 31, 2026	Needham	Ami Fadia	PT Cut	Buy	$45→$43
Aug 10, 2026	UBS	Ashwani Verma	Downgrade	Buy→Neutral	$52→$13
Jul 28, 2026	Canaccord Genuity	Sumant Kulkarni	PT Cut	Buy	$43→$24
Jul 28, 2026	Morgan Stanley	Sean Laaman	Downgrade	Overweight→Equal-Weight	$34→$21
Jul 28, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$45→$26
Jul 24, 2026	Canaccord Genuity	Sumant Kulkarni	PT Raise	Buy	$35→$43
Jul 21, 2026	UBS	Ashwani Verma	PT Raise	Buy	$48→$52
Jul 21, 2026	BMO Capital	Malcolm Hoffman	Initiate	Outperform	$46
Jul 10, 2026	Needham	Ami Fadia	PT Raise	Buy	$42→$45
Jun 25, 2026	Raymond James	Tiago Fauth	Initiate	Strong Buy	$46
Jun 23, 2026	Craig-Hallum	Adam Vogel	PT Cut	Buy	$43→$40
Jun 22, 2026	Needham	Ami Fadia	PT Raise	Buy	$37→$42
Jun 2, 2026	Stifel	Paul Matteis	PT Raise	Buy	$28→$36
May 28, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$45
May 27, 2026	UBS	Ashwani Verma	Initiate	Buy	$48
May 21, 2026	Craig-Hallum	Adam Vogel	Initiate	Buy	$43
May 4, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Initiate	Buy	$45
Apr 8, 2026	Needham	Ami Fadia	Initiate	Buy	$37
Apr 7, 2026	TD Cowen	Joseph Thome	Initiate	Buy	—

Analyst Ratings News

PRO
Guggenheim Initiates Coverage On MapLight Therapeutics with Neutral Rating

Guggenheim analyst Delma Caiati initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Neutral rating.

Benzinga Newsdesk

PRO
Needham Maintains Buy on MapLight Therapeutics, Lowers Price Target to $43

Needham analyst Ami Fadia maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowers the price target from $45 to $43.

Benzinga Newsdesk

PRO
UBS Downgrades MapLight Therapeutics to Neutral, Lowers Price Target to $13

UBS analyst Ashwani Verma downgrades MapLight Therapeutics (NASDAQ:MPLT) from Buy to Neutral and lowers the price target from $52 to $13.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on MapLight Therapeutics, Lowers Price Target to $24

Canaccord Genuity analyst Sumant Kulkarni maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowers the price target from $43 to $24.

Benzinga Newsdesk

PRO
Morgan Stanley Downgrades MapLight Therapeutics to Equal-Weight, Lowers Price Target to $21

Morgan Stanley analyst Sean Laaman downgrades MapLight Therapeutics (NASDAQ:MPLT) from Overweight to Equal-Weight and lowers the price target from $34 to $21.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on MapLight Therapeutics, Lowers Price Target to $26

HC Wainwright & Co. analyst Raghuram Selvaraju maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowers the price target from $45 to $26.

Benzinga Newsdesk

MapLight Therapeutics Inc

MapLight Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Guggenheim Initiates Coverage On MapLight Therapeutics with Neutral Rating

PRO
Needham Maintains Buy on MapLight Therapeutics, Lowers Price Target to $43

PRO
UBS Downgrades MapLight Therapeutics to Neutral, Lowers Price Target to $13

PRO
Canaccord Genuity Maintains Buy on MapLight Therapeutics, Lowers Price Target to $24

PRO
Morgan Stanley Downgrades MapLight Therapeutics to Equal-Weight, Lowers Price Target to $21

PRO
HC Wainwright & Co. Maintains Buy on MapLight Therapeutics, Lowers Price Target to $26

People Also Watch

People Also Watch

MapLight Therapeutics Inc

MapLight Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGuggenheim Initiates Coverage On MapLight Therapeutics with Neutral Rating

PRONeedham Maintains Buy on MapLight Therapeutics, Lowers Price Target to $43

PROUBS Downgrades MapLight Therapeutics to Neutral, Lowers Price Target to $13

PROCanaccord Genuity Maintains Buy on MapLight Therapeutics, Lowers Price Target to $24

PROMorgan Stanley Downgrades MapLight Therapeutics to Equal-Weight, Lowers Price Target to $21

PROHC Wainwright & Co. Maintains Buy on MapLight Therapeutics, Lowers Price Target to $26

People Also Watch

People Also Watch

PRO
Guggenheim Initiates Coverage On MapLight Therapeutics with Neutral Rating

PRO
Needham Maintains Buy on MapLight Therapeutics, Lowers Price Target to $43

PRO
UBS Downgrades MapLight Therapeutics to Neutral, Lowers Price Target to $13

PRO
Canaccord Genuity Maintains Buy on MapLight Therapeutics, Lowers Price Target to $24

PRO
Morgan Stanley Downgrades MapLight Therapeutics to Equal-Weight, Lowers Price Target to $21

PRO
HC Wainwright & Co. Maintains Buy on MapLight Therapeutics, Lowers Price Target to $26